Spectral AI files NTAP application for DeepView burn-wound system
Spectral AI has submitted a New Technology Add-On Payment (NTAP) application to the Centers for Medicare and Medicaid Services (CMS) for its DeepView System, a non-invasive imaging device that uses multispectral technology and a proprietary AI algorithm to assess the healing potential of burn wounds. The Dallas-based company said it pursued the application via the NTAP alternative pathway, with a final CMS determination expected in August 2027.
If approved, NTAP status would take effect in October 2027 and remain in place for approximately three years. Under the programme, qualifying inpatient cases could receive an additional Medicare payment of up to 65% of the estimated incremental cost of deploying the new technology, providing hospitals with a partial offset against adoption costs.
The DeepView System received De Novo Classification from the FDA in May 2026, having previously been granted Breakthrough Device Designation. It also holds UKCA authorisation in the United Kingdom, granted in February 2024. The device acquires images in 0.2 seconds and delivers AI-driven wound assessments within roughly 20 to 25 seconds, drawing on a training dataset the company describes as containing more than 340 billion pixels of clinically validated burn-wound imagery.
Reimbursement as a commercialisation lever
Chief executive Vincent Capone said a successful NTAP award would form a meaningful part of the economic case for hospital systems considering the DeepView System, helping to reduce what he characterised as adoption barriers in inpatient settings. "Additional reimbursement support could improve patient access to care and help reduce adoption barriers for eligible health systems, making it easier to integrate and utilise the DeepView System in appropriate inpatient settings," he said.
The NTAP route is a well-established mechanism for medical technology companies seeking to bridge the reimbursement gap that often slows hospital uptake of newly cleared devices. CMS introduced the programme to ensure that genuinely novel technologies are not penalised under diagnosis-related group payment structures that were calibrated before those technologies existed. Approval is not guaranteed, and the 65% cost-offset ceiling means hospitals would still bear a portion of the incremental expenditure.
Market context
The AI-assisted wound-care diagnostics space has attracted growing attention from medtech developers and health systems alike, driven by the clinical and economic burden of burn injuries, which typically demand lengthy inpatient stays and multiple specialist interventions. Burn care remains a niche but high-acuity segment, and objective, rapid assessment tools address a documented gap: conventional clinical evaluation of burn depth is subject to significant inter-observer variability, particularly in the first 48 to 72 hours following injury.
Spectral AI also holds a contract with the Biomedical Advanced Research and Development Authority (BARDA) through its subsidiary Spectral MD, which provides a degree of non-dilutive revenue support as the company pursues commercialisation. The NTAP application signals that management is now focused on the hospital economics of adoption rather than pure regulatory progress, a natural transition for a device that has cleared its primary regulatory hurdles on both sides of the Atlantic. Investors will watch the August 2027 CMS determination closely as a key indicator of the DeepView System's near-term commercial trajectory.